Abstract
The guinea pig model of recurrent genital herpes simplex virus type 2 (HSV-2) infection was used to test the immunotherapeutic activity of a glycoprotein subunit vaccine. Vaccine formulation consisted of three recombinant herpes simplex virus (HSV) glycoproteins, namely gB1s, gD2t and gE1t, plus aluminium hydroxide [Al(OH)3)] adjuvant. One month after viral challenge, infected animals were therapeutically immunised by seven subcutaneous injections of a low dose of antigens with a weekly interval for the first five and a fortnightly interval for the last two administrations. Results showed that the treatment was highly effective in ameliorating the recidivist pathology of animals, suggesting that this kind of vaccine formulation and administration may be helpful for therapeutic intervention in humans affected by recurrent herpes infections.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Disease Models, Animal
-
Female
-
Glycoproteins / administration & dosage
-
Glycoproteins / immunology
-
Guinea Pigs
-
Herpes Simplex / immunology*
-
Herpes Simplex / prevention & control
-
Herpes Simplex Virus Vaccines / administration & dosage
-
Herpes Simplex Virus Vaccines / immunology*
-
Herpes Simplex Virus Vaccines / therapeutic use*
-
Herpesvirus 2, Human / immunology*
-
Herpesvirus Vaccines / administration & dosage
-
Herpesvirus Vaccines / immunology
-
Herpesvirus Vaccines / therapeutic use
-
Vaccines, Subunit / administration & dosage
-
Vaccines, Subunit / immunology
-
Vaccines, Subunit / therapeutic use
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / immunology
-
Vaccines, Synthetic / therapeutic use
-
Viral Envelope Proteins / administration & dosage
-
Viral Envelope Proteins / immunology*
-
Viral Envelope Proteins / therapeutic use*
Substances
-
Glycoproteins
-
Herpes Simplex Virus Vaccines
-
Herpesvirus Vaccines
-
Vaccines, Subunit
-
Vaccines, Synthetic
-
Viral Envelope Proteins
-
glycoprotein B, herpes simplex virus type 2
-
glycoprotein E, herpes simplex virus type 1
-
herpes simplex virus-1 glycoprotein D vaccine